Patents by Inventor Lars Toleikis
Lars Toleikis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240010749Abstract: Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.Type: ApplicationFiled: August 13, 2021Publication date: January 11, 2024Applicant: Merck Patent GmbHInventors: Jan ANDERL, Sabine RAAB-WESTPHAL, Stefan HECHT, Carl DEUTSCH, Min SHAN, Doreen KÖNNING, Willem N. SLOOT, Felix HART, Christian SCHRÖTER, Lars TOLEIKIS, Nir BERGER
-
Patent number: 11813307Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: GrantFiled: June 4, 2018Date of Patent: November 14, 2023Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
-
Publication number: 20230310629Abstract: Provided are immunoconjugates comprising bispecific anti-MUC 1/EGFR antibodies conjugated to hemiasterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.Type: ApplicationFiled: June 3, 2021Publication date: October 5, 2023Inventors: Christine Knuehl, Lars Toleikis, Christiane Amendt, Achim Doerner, Alice Yam, Xiaofan Li, Ryan Stafford, Robert Henningsen, Sihong Zhou
-
Publication number: 20230312694Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: December 23, 2022Publication date: October 5, 2023Applicants: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Publication number: 20230287082Abstract: B7-H6-based compounds disclosed herein have favorable characteristics. Pharmaceutical compositions containing such a compound, the use of such compounds, and treatment with such pharmaceutical compositions are also disclosed. Methods for preparing a compound with an increased affinity for NKp30 are provided.Type: ApplicationFiled: August 31, 2021Publication date: September 14, 2023Applicant: Merck Patent GmbHInventors: Stefan Zielonka, Lars Toleikis, Simon Krah, Lukas Pekar
-
Patent number: 11603401Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: GrantFiled: June 4, 2018Date of Patent: March 14, 2023Assignees: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Patent number: 11597771Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.Type: GrantFiled: November 21, 2017Date of Patent: March 7, 2023Inventors: Christel Iffland, Christina Esdar, Xinyan Zhao, Qi An, Johannes Yeh, Gang Hao, Lars Toleikis, Vanita Sood, David Nannemann, Robin Lytle, Bjoern Hock
-
Publication number: 20220111064Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.Type: ApplicationFiled: December 16, 2021Publication date: April 14, 2022Applicant: Merck Patent GmbHInventors: Achim DOERNER, Lars Toleikis, Vanita D. Sood, Carolin Sellmann, Christine Knuehl
-
Publication number: 20220089703Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: June 4, 2018Publication date: March 24, 2022Applicants: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Patent number: 11235063Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.Type: GrantFiled: October 27, 2016Date of Patent: February 1, 2022Assignee: Merck Patent GmbHInventors: Achim Doerner, Lars Toleikis, Vanita D. Sood, Carolin Sellmann, Christine Knuehl
-
Publication number: 20210115117Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: June 4, 2018Publication date: April 22, 2021Applicants: Ablynx N.V., Merck Patent GmbHInventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Publication number: 20210008160Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: ApplicationFiled: June 4, 2018Publication date: January 14, 2021Applicants: Merck Patent GmbH, ABLYNX NVInventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
-
Publication number: 20200190216Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.Type: ApplicationFiled: June 4, 2018Publication date: June 18, 2020Applicants: Merck Patent GmbH, ABLYNX NVInventors: Francis DESCAMPS, Gerald BESTE, Guy HERMANS, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL
-
Publication number: 20200140532Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.Type: ApplicationFiled: June 4, 2018Publication date: May 7, 2020Applicant: Ablynx N.V.Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
-
Publication number: 20190367620Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.Type: ApplicationFiled: November 21, 2017Publication date: December 5, 2019Inventors: CHRISTEL IFFLAND, CHRISTINA ESDAR, XINYAN ZHAO, QI AN, JOHANNES YEH, GANG HAO, LARS TOLEIKIS, VANITA SOOD, DAVID NANNEMANN, ROBIN LYTLE, BJOERN HOCK
-
Publication number: 20190248907Abstract: The present invention provides antibodies and heterodimeric immunoglobulin molecules, which bind cMET with high affinity and can be used to target cMET expressing tumor cells. The present invention also discloses methods of generating anti-cMET antibody drug conjugates using the inventive antibodies or heterodimeric immunoglobulin molecules as disclosed herein.Type: ApplicationFiled: September 14, 2017Publication date: August 15, 2019Applicant: MERCK PATENT GMBHInventors: Achim DOERNER, Lars TOLEIKIS, Birgit PIATER, Laura RHIEL, Christine KNUEHL, Carolin SELLMANN, Simon KRAH
-
Publication number: 20180326085Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.Type: ApplicationFiled: October 27, 2016Publication date: November 15, 2018Applicant: MERCK PATENT GMBHInventors: Achim DOERNER, Lars TOLEIKIS, SOOD D. Vanita, Carolin SELLMANN, Christine KNUEHL
-
Patent number: 9546217Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.Type: GrantFiled: July 17, 2009Date of Patent: January 17, 2017Assignee: MAB FACTORY GMBHInventors: Christian Behrens, Holger Thie, Michael Hust, Lars Toleikis, Thomas Schirrmann, Stefan Dübel, Christophe De Romeuf
-
Patent number: 8969318Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.Type: GrantFiled: December 12, 2011Date of Patent: March 3, 2015Assignee: Merck Patent GmbHInventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner
-
Publication number: 20140039042Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.Type: ApplicationFiled: December 12, 2011Publication date: February 6, 2014Applicant: MERCK PATENT GMBHInventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner